Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
AbCellera Biologics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ABCL
Nasdaq
8731
https://www.abcellera.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for AbCellera Biologics Inc
Analysts Just Shipped A Massive Upgrade To Their AbCellera Biologics Inc. (NASDAQ:ABCL) Estimates
- May 13th, 2022 10:06 am
Why AbCellera Biologics Is 10% Lower Today
- May 11th, 2022 4:54 pm
AbCellera Biologics Inc. (ABCL) Beats Q1 Earnings and Revenue Estimates
- May 10th, 2022 9:45 pm
AbCellera Reports Q1 2022 Business Results
- May 10th, 2022 8:05 pm
Ring Energy (REI) to Report Q1 Earnings: What's in Store?
- May 9th, 2022 1:37 pm
AbCellera Biologics Inc. (ABCL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
- May 3rd, 2022 7:00 pm
AbCellera and Empirico Expand Strategic Multi-Target Antibody Discovery Collaboration
- May 3rd, 2022 1:00 pm
AbCellera to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference on May 2, 2022
- Apr 26th, 2022 8:05 pm
3 Biotech Stocks Under $10 to Add to Your Buy List
- Apr 26th, 2022 11:17 am
What Percentage Of AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Do Insiders Own?
- Apr 25th, 2022 5:23 pm
AbCellera to Report First Quarter 2022 Financial Results on May 10, 2022
- Apr 12th, 2022 8:05 pm
AbCellera Presents Data on T Cell Engager Platform at AACR 2022
- Apr 8th, 2022 5:05 pm
AbCellera Biologics Inc. (ABCL) Q4 2021 Earnings Call Transcript
- Feb 25th, 2022 12:00 pm
AbCellera Reports Full Year 2021 Business Results
- Feb 24th, 2022 9:05 pm
AbCellera to Participate Virtually in the Truist Securities AI Symposium – Biotech & Tools
- Feb 23rd, 2022 9:05 pm
AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19
- Feb 11th, 2022 11:58 pm
AbCellera to Present Virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022
- Feb 11th, 2022 9:05 pm
Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatments
- Feb 11th, 2022 12:40 am
AbCellera to Report Full Year 2021 Financial Results on February 24, 2022
- Jan 27th, 2022 9:05 pm
Boasting A 22% Return On Equity, Is AbCellera Biologics Inc. (NASDAQ:ABCL) A Top Quality Stock?
- Jan 25th, 2022 9:05 am
Scroll